Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed advanced solid tumors for which curative standard treatments are not available
• Ten additional patients with extensive stage small cell lung cancer are accrued to the expanded cohort once a maximum tolerate dose (or a dose for further exploration) is determined
• Must be chemotherapy naive
• Measurable or evaluable disease
• Prior irradiated disease sites are considered measurable if there is clear disease progression following radiation therapy
• No uncontrolled brain or leptomeningeal metastases (including those requiring glucocorticoids)

PATIENT CHARACTERISTICS:

• Zubrod performance status 0-2
• Life expectancy > 3 months
• Granulocyte count ≥ 1,500/mm^3
• Platelet count ≥ 100,000/mm^3
• Creatinine ≤ 1.3 mg/dL OR creatinine clearance > 40 mL/min
• Serum bilirubin ≤ 1.5 mg/dL (regardless of liver involvement)
• SGOT ≤ 3 times upper limit of normal (ULN)
• INR ≤ 1.3 (≤ 3 if on anticoagulation)
• Fasting serum cholesterol ≤ 300 mg/dL*
• Fasting triglycerides ≤ 2.5 times ULN*
• No severe and/or uncontrolled medical co-morbidities or other conditions that could affect participation in the study including, but not limited to, the following:
• Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction ≤ 6 months prior to first study treatment
• Serious uncontrolled cardiac arrhythmia
• Severely impaired lung function
• Active (acute or chronic) or uncontrolled infection
• Non-malignant medical illness that is uncontrolled or that the control may be jeopardized by the study therapy
• Liver disease (i.e., cirrhosis, chronic active hepatitis, chronic persistent hepatitis)
• No uncontrolled diabetes mellitus (i.e., fasting serum glucose > 1.5 times ULN)
• No HIV seropositivity
• Not pregnant or nursing
• Fertile patients must use effective contraception
• No oral, implantable, or injectable contraceptives
• No impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of everolimus (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)
• No active, bleeding diathesis
• No known hypersensitivity to everolimus or other rapamycins (e.g., sirolimus, temsirolimus) or to its excipients
• Must be able to take and retain oral medication
• No peripheral neuropathy > grade 1 as per NCI CTCAE vs. 3 NOTE: *In case one or both of these thresholds are exceeded, the patient can only be included after initiation of appropriate lipid-lowering medication.

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• Recovered from prior therapy
• More than 3 weeks since prior and no concurrent investigational drugs
• At least 3 weeks since prior chemotherapy
• At least 2 weeks since prior major surgery or completion of radiotherapy
• No immunization with attenuated live vaccines within the past week or during study therapy
• No prior treatment with an mTOR inhibitor (e.g., sirolimus, temsirolimus, or everolimus)
• No chronic treatment with systemic steroids or other immunosuppressive agents
• No concurrent oral anti-vitamin K medication (except low dose coumadin)
• No concurrent medications interfering with everolimus
• No other concurrent anticancer agents